Acute pulmonary coccidioidomycosis
ICD-10 B38.0 · ICD-11 1F25.00

Treatment of Acute Pulmonary Coccidioidomycosis with Mild or Nondebilitating Symptoms (Uncomplicated Presentation, No Immunosuppression)

This protocol applies to adults with uncomplicated coccidioidal pneumonia whose symptoms are mild or nondebilitating — or whose clinical illness has substantially improved or resolved by the time of diagnosis — and who have no overt immunosuppressing condition.

Clinical Scenario

Uncomplicated coccidioidal pneumonia with mild or nondebilitating symptoms, or substantially improved or resolved clinical illness at the time of diagnosis; no overt immunosuppressing condition.

Treatment Approach (partial)

When pharmacologic treatment is warranted in nonpregnant adults with this presentation, management centers on an orally absorbed azole antifungal. The specific agent selection, dosing strategy, and treatment duration depend on the individual clinical response and are detailed in the full protocol.

Treatment Goals

Resolution of signs, symptoms, and inflammatory markers, with stabilization of serologies and chest radiographs.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciw360

  • We recommend patient education, close observation, and supportive measures such as reconditioning physical therapy for patients who appear to have mild or nondebilitating symptoms, or who have substantially improved or resolved their clinical illness by the time of diagnosis (strong, low).
  • If treatment is begun in nonpregnant adults, the treatment should be an orally absorbed azole antifungal (eg, fluconazole) at a daily dose of ≥400 mg (strong, low).
  • If treatment of early uncomplicated coccidioidal infection is instituted, the usual dose for adults is 400 mg daily. Some experts would recommend 800 mg daily.
  • The duration is not certain, although many experts would recommend a treatment duration ranging from 3 to 6 months or longer, depending on the clinical response.
  • Treatment can be discontinued when the patient's signs, symptoms, and inflammatory markers have resolved, and serologies and radiographs have stabilized.
View source ↗